Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Treatment of Bone Marrow to Prevent Graft-Versus-Host Disease in Patients With Acute or Chronic Leukemia Undergoing Bone Marrow Transplantation

This study has been completed.
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: January 28, 2000
Last updated: July 9, 2013
Last verified: February 2002

RATIONALE: Bone marrow that has been treated to remove certain white blood cells may reduce the chance of developing graft-versus-host disease following bone marrow transplantation.

PURPOSE: Randomized phase II/III trial to compare the effectiveness of treated bone marrow with that of untreated bone marrow in preventing graft-versus-host disease in patients with acute or chronic leukemia who are undergoing bone marrow transplantation.

Condition Intervention Phase
Graft Versus Host Disease
Myelodysplastic Syndromes
Biological: anti-thymocyte globulin
Biological: filgrastim
Drug: cyclophosphamide
Drug: fludarabine phosphate
Drug: methylprednisolone
Drug: tacrolimus
Procedure: allogeneic bone marrow transplantation
Procedure: in vitro-treated bone marrow transplantation
Radiation: radiation therapy
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Multi-Center, Open Label, Randomized, Active Controlled Phase II/III Clinical Trial to Evaluate the Safety and Efficacy of Processed Unrelated Bone Marrow in Patients With Acute or Chronic Leukemia

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Study Start Date: March 2000
Study Completion Date: May 2003
Detailed Description:


  • Compare the efficacy of processed (cell depleted) vs unprocessed (conventional) unrelated bone marrow transplantation in reducing grade III/IV acute graft vs host disease (GVHD) in patients with acute or chronic leukemia or myelodysplastic syndromes.
  • Compare the safety of these regimens in these patients.
  • Compare the disease-free survival rate at 100 days and at 6 months in patients treated with these regimens.
  • Compare the time to engraftment and percent engraftment in patients treated with these regimens.
  • Compare the reduction rate of grade II or greater acute and chronic GVHD in patients treated with these regimens.

OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified according to degree of HLA matching and disease (chronic vs acute). Acute myelogenous leukemia patients are further stratified according to prior myelodysplastic syndromes (yes vs no). Patients are randomized to one of two bone marrow transplantation arms.

All patients receive a conditioning regimen comprising fludarabine IV on day -6, cyclophosphamide IV on days -5 and -4, anti-thymocyte globulin IV on days -4 and -2, and total body irradiation on days -3 to 0. Patients also receive methylprednisolone IV every 12 hours for 4 doses on days -2 to 0. Tacrolimus IV is administered continuously on day -1 and continues either orally or IV for 6 months. Bone marrow is infused on day 0. Filgrastim (G-CSF) is administered subcutaneously from day 0 until blood counts recover.

  • Arm I: Patients receive allogeneic bone marrow that has been processed to produce a mononuclear cell preparation.
  • Arm II: Patients receive unprocessed allogeneic bone marrow. Patients are followed weekly for 100 days and then at 6 months.

PROJECTED ACCRUAL: A total of 260 patients will be accrued for this study within 17 months.


Ages Eligible for Study:   12 Years to 50 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Diagnosis of one of the following:

    • Acute myelogenous leukemia (AML) or acute lymphocytic leukemia (ALL) in first early relapse, second remission, or subsequent remission
    • AML in first complete remission with one of the following adverse features:

      • Antecedent hematologic disorder such as myelodysplasia
      • AML resulting from prior chemotherapy or radiotherapy
      • More than 1 course of induction chemotherapy to achieve remission or adverse cytogenetics such as Philadelphia chromosome 9:22, +8, +11; abnormal 12p; or deletions of chromosomes 5, 7, or 20 (3:3)
    • ALL in first complete remission with poor risk cytogenetics such as

      • Philadelphia chromosome 9:22, 8:14, or 4:11 OR
      • WBC greater than 100,000/mm3 OR
      • Time to achieve complete remission more than 4 weeks
    • Chronic myelogenous leukemia in chronic or accelerated phase
    • Myelodysplastic syndromes

      • Refractory anemia with excess blasts (RAEB) OR
      • RAEB in transformation
  • Unrelated bone marrow donor available

    • If matched at 6 of 6 HLA-A, -B, and -DR loci, patient must be 12 to 50 years
    • If matched at 5 of 6 loci, patient must be 12 to 35 years
  • No matched sibling donor available
  • No uncontrolled CNS leukemia



  • See Disease Characteristics
  • 12 to 50

Performance status:

  • Karnofsky 70-100%

Life expectancy:

  • At least 12 weeks


  • See Disease Characteristics


  • Bilirubin less than 2.5 times upper limit of normal (ULN)
  • SGOT or SGPT less than 2.5 times ULN


  • Creatinine no greater than 1.5 mg/dL


  • LVEF greater than 50% without medication


  • DLCO and FVC at least 50% predicted


  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No other serious medical illness
  • No uncontrolled diabetes mellitus
  • No uncontrolled and/or active infection
  • HIV negative


Biologic therapy:

  • At least 3 weeks since prior immunotherapy and recovered
  • At least 1 year since prior autologous transplantation
  • No prior allogeneic transplantation


  • See Disease Characteristics
  • At least 3 weeks since prior chemotherapy (except hydroxyurea) and recovered

Endocrine therapy:

  • At least 3 weeks since prior hormonal therapy and recovered


  • See Disease Characteristics
  • At least 3 weeks since prior radiotherapy and recovered
  • No prior radiotherapy at doses that would preclude study


  • Not specified
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00004255

United States, California
University of California San Diego Cancer Center
La Jolla, California, United States, 92093-0658
United States, Colorado
Presbyterian-St Luke's Medical Center
Denver, Colorado, United States, 80218
United States, District of Columbia
Lombardi Cancer Center
Washington, District of Columbia, United States, 20007
United States, Florida
Shands Hospital and Clinics, University of Florida
Gainesville, Florida, United States, 32610-100277
United States, Indiana
Indiana Blood and Marrow Transplantation
Indianapolis, Indiana, United States, 46202
United States, Kentucky
James Graham Brown Cancer Center
Louisville, Kentucky, United States, 40202
United States, Michigan
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, United States, 48201-1379
United States, New York
University of Rochester Cancer Center
Rochester, New York, United States, 14642
New York Medical College
Valhalla, New York, United States, 10595
United States, Oklahoma
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States, 73190
United States, Oregon
Oregon Cancer Center
Portland, Oregon, United States, 97201-3098
United States, Pennsylvania
Hahnemann University Hospital
Philadelphia, Pennsylvania, United States, 19102-1192
United States, Texas
University of Texas - MD Anderson Cancer Center
Houston, Texas, United States, 77030-4009
South Texas Cancer Institute
San Antonio, Texas, United States, 78229
United States, Virginia
Massey Cancer Center
Richmond, Virginia, United States, 23298-0037
Sponsors and Collaborators
Chimeric Therapies
Study Chair: James N. Lowder, MD Chimeric Therapies
  More Information Identifier: NCT00004255     History of Changes
Other Study ID Numbers: CHIMERIC-HM01
CDR0000067502 ( Registry Identifier: PDQ (Physician Data Query) )
Study First Received: January 28, 2000
Last Updated: July 9, 2013

Keywords provided by National Cancer Institute (NCI):
recurrent childhood acute lymphoblastic leukemia
recurrent childhood acute myeloid leukemia
recurrent adult acute myeloid leukemia
recurrent adult acute lymphoblastic leukemia
chronic phase chronic myelogenous leukemia
accelerated phase chronic myelogenous leukemia
adult acute myeloid leukemia in remission
adult acute lymphoblastic leukemia in remission
childhood acute myeloid leukemia in remission
childhood acute lymphoblastic leukemia in remission
refractory anemia with excess blasts
refractory anemia with excess blasts in transformation
secondary acute myeloid leukemia
de novo myelodysplastic syndromes
previously treated myelodysplastic syndromes
secondary myelodysplastic syndromes
graft versus host disease
childhood myelodysplastic syndromes

Additional relevant MeSH terms:
Myelodysplastic Syndromes
Graft vs Host Disease
Pathologic Processes
Neoplasms by Histologic Type
Bone Marrow Diseases
Hematologic Diseases
Precancerous Conditions
Immune System Diseases
Antilymphocyte Serum
Fludarabine phosphate
Methylprednisolone Hemisuccinate
Prednisolone acetate
Methylprednisolone acetate
Prednisolone hemisuccinate
Prednisolone phosphate
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating processed this record on April 27, 2017